Category Archives: Global News Feed

Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

See the original post:
Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement

Read the original here:
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on...

PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment

View original post here:
Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic...

Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1

More:
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors

Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis

Read this article:
Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or...

Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotechnology Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotechnology

Follow this link:
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs. All new appointments are effective July 1, 2022.

View post:
HOOKIPA Announces Executive Leadership Changes

Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board

See original here:
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

DENVER, June 21, 2022 (GLOBE NEWSWIRE) -- LaunchPad Café, Ltd, the finance subsidiary of Ventana Biotech, Inc. (OTC: VNTA), is pleased to announce that it has contracted for its first financing client as a public company.

Go here to read the rest:
LaunchPad Café, LTD, a subsidiary of Ventana Biotech, Inc. (VNTA), Announces its First financing client

SYDNEY, June 21, 2022 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Friday, 15th July 2022 at 8:30 a.m. (Australian Eastern Standard Time).

Read more:
Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum